Literature DB >> 11176486

A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy.

M Graefen1, A Haese, U Pichlmeier, P G Hammerer, J Noldus, K Butz, A Erbersdobler, R P Henke, U Michl, S Fernandez, H Huland.   

Abstract

PURPOSE: Nerve sparing radical prostatectomy for prostate cancer should be restricted to patients who harbor tumors without capsular penetration. To our knowledge the selection criteria for nerve sparing radical prostatectomy are not clearly defined. We investigated a panel of preoperative tumor characteristics with respect to their ability to predict organ confined tumor growth for each lobe of the prostate to indicate unilateral or bilateral nerve sparing radical prostatectomy.
MATERIALS AND METHODS: Nine preoperative tumor characteristics in 278 patients with clinically localized prostate cancer were included in retrospective univariate and multivariate tree structured regression analysis. The association of clinical stage, serum prostate specific antigen (PSA), PSA density, and results of transrectal ultrasound and systematic sextant biopsy, including a quantitative assessment of cancer in the biopsies with organ confined tumor growth, was statistically evaluated. Except for serum PSA and PSA density preoperative characteristics were considered separately for each prostate lobe. Multivariate analysis results were validated prospectively in 353 patients.
RESULTS: On univariate analysis the number of positive biopsies was the most useful single parameter with a positive predictive value of 83% in 274 lobes and a negative predictive value of 55%, followed by mm. of tumor in the biopsy. Of all characteristics included in multivariate analysis only the number of biopsies with high grade cancer, the number of positive biopsies and serum PSA were independent for predicting organ confined cancer. When PSA was less than 10 ng./ml. and not more than 1 biopsy with high grade cancer was identified in a lobe, organ confined tumor growth was present in 86.1% of cases. On prospective validation the same criteria led to an 88.5% incidence of organ confined prostate cancer. Pooling the 2 most favorable groups led to 391 prostate lobes (70.8% of those investigated) with a positive predictive value of 82.1% (95% confidence interval 77.9% to 85.8%). Using the multivariate approach more prostate lobes were assigned to a favorable risk group than on univariate analysis. Clinical stage and simple Gleason grade did not contribute independent information for predicting organ confined disease.
CONCLUSIONS: Quantifying cancer and high grade cancer by systematic biopsy and serum PSA concentration are useful preoperative characteristics for predicting organ confined prostate cancer. Side specific analysis of these parameters is a flexible and reliable tool for selecting patients for nerve sparing radical prostatectomy.

Entities:  

Mesh:

Year:  2001        PMID: 11176486

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  24 in total

Review 1.  [Indications for and results of radical prostatectomy].

Authors:  M Graefen; P G Hammerer; A Haese; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

2.  [Technique of nerve-sparing radical retropubic prostatectomy].

Authors:  M Graefen; H Huland
Journal:  Urologe A       Date:  2004-02       Impact factor: 0.639

3.  Prevalence and risk factors of contralateral extraprostatic extension in men undergoing radical prostatectomy for unilateral disease at biopsy: A global multi-institutional experience.

Authors:  Marc Bienz; Pierre-Alain Hueber; Vincent Trudeau; Abdullah M Alenizi; Roger Valdivieso; Modar Alom; Mevlana Derya Balbay; Abdullah Erdem Canda; Vladimir Mouraviev; David M Albala; Assaad El-Hakim; Quoc-Dien Trinh; Mathieu Latour; Fred Saad; Kevin C Zorn
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

Review 4.  Role of nomograms for prostate cancer in 2007.

Authors:  Felix K-H Chun; Pierre I Karakiewicz; Hartwig Huland; Markus Graefen
Journal:  World J Urol       Date:  2007-02-27       Impact factor: 4.226

5.  Erectile Function Recovery after Radical Prostatectomy in Men with High Risk Features.

Authors:  Pedro Recabal; Melissa Assel; John E Musser; Ronald J Caras; Daniel D Sjoberg; Jonathan A Coleman; John P Mulhall; Raul O Parra; Peter T Scardino; Karim Touijer; James A Eastham; Vincent P Laudone
Journal:  J Urol       Date:  2016-02-22       Impact factor: 7.450

6.  [Complications of radical retropubic prostatectomies based on the Martin criteria].

Authors:  B Löppenberg; J Noldus; J Palisaar
Journal:  Urologe A       Date:  2011-11       Impact factor: 0.639

7.  Safe-R: a novel score, accounting for oncological safe nerve-sparing at radical prostatectomy for localized prostate cancer.

Authors:  Andreas Becker; Carolina Coelius; Meike Adam; Pierre Tennstedt; Luis Kluth; Thomas Steuber; Hans Heinzer; Markus Graefen; Thorsten Schlomm; Uwe Michl
Journal:  World J Urol       Date:  2014-03-26       Impact factor: 4.226

Review 8.  Critical review of prostate cancer predictive tools.

Authors:  Shahrokh F Shariat; Michael W Kattan; Andrew J Vickers; Pierre I Karakiewicz; Peter T Scardino
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

9.  Preoperative nomograms for predicting extracapsular extension in Korean men with localized prostate cancer: a multi-institutional clinicopathologic study.

Authors:  Jae Seung Chung; Han Yong Choi; Hae-Ryoung Song; Seok-Soo Byun; Seong il Seo; Cheryn Song; Jin Seon Cho; Sang Eun Lee; Hanjong Ahn; Eun Sik Lee; Won-Jae Kim; Moon Kee Chung; Tae Young Jung; Ho Song Yu; Young Deuk Choi
Journal:  J Korean Med Sci       Date:  2010-09-17       Impact factor: 2.153

Review 10.  [Transrectal ultrasound-guided punch biopsies of the prostate. Indication, technique, results, and complications].

Authors:  J Palisaar; T Eggert; M Graefen; A Haese; H Huland
Journal:  Urologe A       Date:  2003-09       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.